Loading...

KalVista Pharmaceuticals ($KALV)

Stock Image

KALV Overview

KalVista Pharmaceuticals, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs.The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE.The company is headquartered in Cambridge, Massachusetts. (From: StockAnalysis.com)

MORE ABOUT KalVista Pharmaceuticals

Stay up to date with the best of Bullish each week.

BULLISH WEEKLY

Stay up to date with the best of Bullish each week.